Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression - PubMed (original) (raw)

Lipopolysaccharide is a potent monocyte/macrophage-specific stimulator of human immunodeficiency virus type 1 expression

R J Pomerantz et al. J Exp Med. 1990.

Abstract

Lipopolysaccharide (LPS) potently stimulates human immunodeficiency virus type 1-long terminal repeat (HIV-1-LTR) CAT constructs transfected into monocyte/macrophage-like cell lines but not a T cell line. This effect appears to be mediated through the induction of nuclear factor kappa B (NF-kappa B). Electrophoretic mobility shift assays demonstrate that LPS induces a DNA binding activity indistinguishable from NF-kappa B in U937 and THP-1 cells. LPS is also shown to dramatically increase HIV-1 production from a chronically infected monocyte/macrophage-like cloned cell line, U1, which produces very low levels of HIV-1 at baseline. The stimulation of viral production from this cell line occurs only if these cells are treated with granulocyte/macrophage colony-stimulating factor (GM-CSF) before treatment with LPS. This stimulation of HIV-1 production is correlated with an increase in the level of HIV-1 RNA and and activation of NF-kappa B. LPS is not able to induce HIV-1 production in a cloned T cell line. The effect of LPS on HIV-1 replication occurs at picogram per milliliter concentrations and may be clinically significant in understanding the variability of the natural history of HIV-1 infection.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Anal Biochem. 1976 May 7;72:248-54 - PubMed
    1. J Exp Med. 1990 Jan 1;171(1):35-47 - PubMed
    1. Mol Cell Biol. 1982 Sep;2(9):1044-51 - PubMed
    1. Nucleic Acids Res. 1983 Mar 11;11(5):1475-89 - PubMed
    1. Ann N Y Acad Sci. 1966 Jun 30;133(2):668-84 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources